Irene Dy, MD
Hematology · Castro Valley, CANPI 1528393063
Payments from drug & device makers
Across 58 payments — averaging $80.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$461
- Daiichi Sankyo Inc.$352
- E.r. Squibb & Sons, L.L.C.$339
- Johnson & Johnson$267
- Novocure GmbH$250
- Lilly USA, LLC$226
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$2505%
- Food & beverage$4,34193%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $461 |
| Daiichi Sankyo Inc. | 4 | $352 |
| E.r. Squibb & Sons, L.L.C. | 3 | $339 |
| Johnson & Johnson | 4 | $267 |
| Novocure GmbH | 1 | $250 |
| Lilly USA, LLC | 5 | $226 |
| Incyte Corporation | 2 | $224 |
| GSK | 2 | $206 |
| Agios Pharmaceuticals, Inc. | 2 | $192 |
| Galvanize Therapeutics, Inc | 1 | $158 |
| Puma Biotechnology, Inc. | 2 | $154 |
| Secura Bio, Inc. | 2 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $151 |
| Sanofi | 2 | $146 |
| Foundation Medicine, Inc. | 2 | $145 |
| Amgen | 2 | $141 |
| Genentech USA, Inc. | 2 | $133 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Taiho Oncology, Inc. | 1 | $125 |
| Karyopharm Therapeutics Inc. | 1 | $121 |
| Novartis | 1 | $121 |
| Tempus AI, Inc | 4 | $100 |
| Bayer | 1 | $99 |
| Pfizer | 1 | $75 |
| Astellas Pharma US Inc | 1 | $72 |
| Rigel Pharmaceuticals, Inc. | 1 | $65 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $55 |
| AbbVie | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$221
- PYRUKYND$175
- INJECTAFER$169
- ALIYA SYSTEM$158
- INQOVI$125
- SARCLISA$125
- TAZVERIK$125
- MONJUVI$125
- Enhertu$125
- BLENREP$125
- IMBRUVICA$123
- NINLARO$123
- TAGRISSO$123
- FOUNDATIONONE$123
- FOUNDATIONONE HEME$123
- FOUNDATIONONE CDX$123
- FOUNDATIONFOCUS$123
- FOUNDATIONONE LIQUID CDX$123
- LUMAKRAS$122
- CALQUENCE$121
How this compares
$4,687 in reported general payments places this provider in the 35th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 35 | $515 |
| Tamoxifen Citrate | 12 | $416 |
| Hydroxyurea | 15 | $309 |
| Letrozole | 17 | $223 |
| Alendronate Sodium | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Other hematology in Castro Valley
- Tait ShanafeltStanford$441.4M
- Alex HerreraDuarte$50.9M
- Hope RugoSan Francisco$23.8M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.